OXiGENE Announces Phase 2 Data on ZYBRESTAT to Treat the Eye Disease, Polypoidal Choroidal Vasculopathy (PCV), Presented at the American Academy of Ophthalmology 2012 Annual Meeting
November 12, 2012 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced the...
OXiGENE Reports Third Quarter 2012 Financial Results
November 08, 2012 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 8, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial...
OXiGENE Announces Presentation at BIO-Europe Conference on November 14th
November 05, 2012 16:05 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 5, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...
OXiGENE Announces Third Quarter 2012 Earnings Conference Call and Webcast
November 01, 2012 09:30 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 1, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report third...
OXiGENE Announces Agreement With FDA on Special Protocol Assessment for a Phase 3 Trial of ZYBRESTAT(R) in Anaplastic Thyroid Cancer
September 17, 2012 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that it...
OXiGENE to Present Data Showing Importance of Local Site Pathology Confirmation in Phase 2/3 Clinical Trial of Zybrestat(R) in Anaplastic Thyroid Cancer
September 07, 2012 06:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 7, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced the...
OXiGENE Expands ZYBRESTAT Named Patient Program With Azanta A/S
August 22, 2012 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 22, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that the...
OXiGENE Reports Second Quarter 2012 Financial Results
August 08, 2012 16:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 8, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial...
OXiGENE Announces Phase 2 Ovarian Cancer Trial of ZYBRESTAT(R) Plus Bevacizumab Achieves Important Interim Safety Objective
August 06, 2012 06:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 6, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced today...
OXiGENE Receives Notice Related to NASDAQ Minimum Closing Bid Price Rule
June 27, 2012 06:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., June 27, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced it has...